Top

BMC Health Services Research

Published in:

Open Access 01-12-2021 | Care | Research

Multimorbidity and achievement of treatment goals among patients with type 2 diabetes: a primary care, real-world study

Authors: Eveliina Heikkala, Ilona Mikkola, Jari Jokelainen, Markku Timonen, Maria Hagnäs

Published in: BMC Health Services Research | Issue 1/2021

Abstract

Background

Type 2 diabetes (T2D), with its prevalence and disability-causing nature, is a challenge for primary health care. Most patients with T2D are multimorbid, i.e. have one or more long-term diseases in addition to T2D. Multimorbidity may play a role in the achievement of T2D treatment targets, but is still not fully understood. The aims of the present cross-sectional, register-based study were to evaluate the prevalence and the most common patterns of multimorbidity among patients with T2D; and to study the potential associations between multimorbidity and treatment goal achievement, including measurements of glycosylated haemoglobin A1c (HbA1c), low-density lipoprotein (LDL) and systolic blood pressure (sBP).

Methods

The study population consisted of 4545 primary care patients who received a T2D diagnosis between January 2011 and July 2019 in Rovaniemi Health Centre, Finland. Data on seven long-term concordant (T2D-related) diseases, eight long-term discordant (non-T2D-related) diseases, potential confounders (age, sex, body mass index, prescribed medication), and the outcomes studied were collected from patients’ records. Logistic regression models with odds ratios (ORs) and 95 % confidence intervals (CIs) were assessed to determine the associations between multimorbidity and the achievement of treatment targets.

Results

Altogether, 93 % of the patients had one or more diseases in addition to T2D, i.e. were considered multimorbid. Furthermore, 21 % had only concordant disease(s) (Concordant subgroup), 8 % had only discordant disease(s) (Discordant subgroup) and 64 % had both (Concordant and discordant subgroup). As either single diseases or in combination with others, hypertension, musculoskeletal (MS) disease and hyperlipidaemia were the most prevalent multimorbidity patterns. Being multimorbid in general (OR 1.32, CI 1.01–1.70) and belonging to the Concordant (OR 1.45, CI 1.08–1.95) and Concordant and discordant (OR 1.31, CI 1.00–1.72) subgroups was associated with achievement of the HbA1c treatment target. Belonging to the Concordant and discordant subgroup was related to meeting the LDL treatment target (OR 1.31, CI 1.00–1.72).

Conclusions

Multimorbidity, including cardiovascular risk and the musculoskeletal disease burden, was extremely prevalent among the T2D patients who consulted primary health care. Primary care clinicians should survey the possible co-existence of long-term diseases among T2D patients to help maintain adequate treatment of T2D.

GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–858. https://doi.org/10.1016/S0140-6736(18)32279-7.CrossRef

Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88–98. https://doi.org/10.1038/nrendo.2017.151.CrossRefPubMed

Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14. https://doi.org/10.1016/j.diabres.2009.10.007.CrossRefPubMed

Bellou V, Belbasis L, Tzoulaki I, Evangelou E. Risk factors for type 2 diabetes mellitus: an exposure-wide umbrella review of meta-analyses. PLoS One. 2018;13(3):e0194127. https://doi.org/10.1371/journal.pone.0194127.CrossRefPubMedPubMedCentral

Mahajan A, Taliun D, Thurner M, Robertson NR, Torres JM, Rayner NW, et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nat Genet. 2018;50:1505–13. https://doi.org/10.1038/s41588-018-0241-6.CrossRefPubMedPubMedCentral

Zhang Y, Pan XF, Chen J, Xia L, Cao A, Zhang Y, et al. Combined lifestyle factors and risk of incident type 2 diabetes and prognosis among individuals with type 2 diabetes: a systematic review and meta-analysis of prospective cohort studies. Diabetologia. 2020;63(1):21–33. https://doi.org/10.1007/s00125-019-04985-9.CrossRefPubMed

Chiang JI, Furler J, Mair F, Jani BD, Nicholl BI, Thuraisingam S, et al. Associations between multimorbidity and glycaemia (HbA1c) in people with type 2 diabetes: cross-sectional study in Australian general practice. BMJ Open. 2020;10:e039625. https://doi.org/10.1136/bmjopen-2020-039625.CrossRefPubMedPubMedCentral

Zghebi SS, Steinke DT, Rutter MK, Ashcroft DM. Eleven-year multimorbidity burden among 637 255 people with and without type 2 diabetes: a population-based study using primary care and linked hospitalisation data. BMJ Open. 2020;10:e033866. https://doi.org/10.1136/bmjopen-2019-033866.CrossRefPubMed

Chiang JI, Hanlon P, Li TC, Jani BD, Manski-Nankervis JA, Furler J, et al. Multimorbidity, mortality, and HbA1c in type 2 diabetes: a cohort study with UK and Taiwanese cohorts. PLoS Med. 2020;17(5):e1003094. https://doi.org/10.1371/journal.pmed.1003094.CrossRefPubMedPubMedCentral

10.

Aga F, Dunbar SB, Kebede T, Gary RA. The role of concordant and discordant comorbidities on performance of self-care behaviors in adults with type 2 diabetes: a systematic review. Diabetes Metab Syndr Obes. 2019;12:333–56. https://doi.org/10.2147/DMSO.S186758.CrossRefPubMedPubMedCentral

11.

Al-Musawe L, Martins AP, Raposo JF, Torre C. The association between polypharmacy and adverse health consequences in elderly type 2 diabetes mellitus patients; a systematic review and meta-analysis. Diabetes Res Clin Pract. 2019;155:107804. https://doi.org/10.1016/j.diabres.2019.107804.CrossRefPubMed

12.

McCoy RG, Lipska KJ, Van Houten HK, Shah ND. Association of cumulative multimorbidity, glycemic control, and medication use with hypoglycemia-related emergency department visits and hospitalizations among adults with diabetes. JAMA Netw Open. 2020;3(1):e1919099. https://doi.org/10.1001/jamanetworkopen.2019.19099.CrossRefPubMedPubMedCentral

13.

Li R, Bilik D, Brown MB, Zhang P, Ettner SL, Ackermann RT, et al. Medical costs associated with type 2 diabetes complications and comorbidities. Am J Manag Care. 2013;19(5):421–30.PubMedPubMedCentral

14.

American Diabetes Association. Diabetes Care. 2019;42(Supplement 1):S103–23. https://doi.org/10.2337/dc19-S010.

15.

Piette JD, Kerr EA. The impact of comorbid chronic conditions on diabetes care. Diabetes Care. 2006;29(3):725–31. https://doi.org/10.2337/diacare.29.03.06.dc05-2078.CrossRefPubMed

16.

Magnan EM, Palta M, Johnson HM, Bartels CM, Schumacher JR, Smith MA. The impact of a patient’s concordant and discordant chronic conditions on diabetes care quality measures. J Diabetes Complications. 2015;29(2):288–94. https://doi.org/10.1016/j.jdiacomp.2014.10.003.CrossRefPubMed

17.

Magnan EM, Bolt DM, Greenlee RT, Fink J, Smith MA. Stratifying patients with diabetes into clinically relevant groups by combination of chronic conditions to identify gaps in quality of care. Health Serv Res. 2018;53(1):450–68. https://doi.org/10.1111/1475-6773.12607.CrossRefPubMed

18.

Ricci-Cabello I, Stevens S, Kontopantelis E, Dalton AR, Griffiths RI, Campbell JL, et al. Impact of the prevalence of concordant and discordant conditions on the quality of diabetes care in family practices in England. Ann Fam Med. 2015;13(6):514–22. https://doi.org/10.1370/afm.1848.CrossRefPubMedPubMedCentral

19.

Woodard LD, Urech T, Landrum CR, Wang D, Petersen LA. Impact of comorbidity type on measures of quality for diabetes care. Med Care. 2011;49(6):605–10. https://doi.org/10.1097/MLR.0b013e31820f0ed0.CrossRefPubMedPubMedCentral

20.

Chiang JI, Jani BD, Mair FS, Nicholl BI, Furler J, O’Neal D, et al. Associations between multimorbidity, all-cause mortality and glycaemia in people with type 2 diabetes: a systematic review. PLoS One. 2018;13(12):e0209585. https://doi.org/10.1371/journal.pone.0209585.CrossRefPubMedPubMedCentral

21.

Nguyen H, Manolova G, Daskalopoulou C, Vitoratou S, Prince M, Prina AM. Prevalence of multimorbidity in community settings: a systematic review and meta-analysis of observational studies. J Comorb. 2019;9:1–15. https://doi.org/10.1177/2235042X19870934.CrossRef

22.

Willadsen TG, Bebe A, Koster-Rasmussen R, Jarbol DE, Guassora AD, Waldorff FB, et al. The role diseases, risk factors and symptoms in the definition of multimorbidity – a systematic review. Scan J Prim Health Care. 2016;34(2):112–21. https://doi.org/10.3109/02813432.2016.1153242.CrossRef

23.

Diederich C, Berger K, Bartels B. The measurement of multiple chronic diseases - a systematic review on existing multimorbidity indices. J Gerontol A Biol Sci Med Sci. 2011;66(3):301–11. https://doi.org/10.1093/gerona/glq208.CrossRef

24.

Parati G, Stergiou GS, Asmar R, Bilo G, de Leeuw P, Imai Y, et al. European society of hypertension guidelines for blood pressure monitoring at home: a summary report of the second international consensus conference on home blood pressure monitoring. J Hypertens. 2008;26(8):1505–26. https://doi.org/10.1097/HJH.0b013e328308da66.CrossRefPubMed

25.

Type 2 diabetes. Current Care Guidelines. Working groups set up by the Finnish Medical Society Duodecim, the Finnish Society of Internal Medicine, the Medical Advisory Board of the Finnish Diabetes Society. Helsinki: The Finnish Medical Society Duodecim, 2020 (referred April, 6, 2021). Available online at: www.kaypahoito.fi

26.

Hypertension. Current Care Guidelines. Working groups set up by the Finnish Medical Society Duodecim, the Finnish Hypertension Society. Helsinki: The Finnish Medical Society Duodecim, 2020 (referred April, 6, 2021). Available online at: www.kaypahoito.fi

27.

World Health Organization. Obesity: Preventing and Managing the Global Epidemic: Report on a WHO Consultation (WHO Technical Report Series 894). Geneva: World Health Organization; 2000.

28.

Lang VB, Marković BB. Prevalence of comorbidity in primary care patients with type 2 diabetes and its association with elevated HbA1c: a cross-sectional study in Croatia. Scand J Prim Health Care. 2016;34(1):66–72. https://doi.org/10.3109/02813432.2015.1132886.CrossRef

29.

Pouplier S, Olsen MÅ, Willadsen TG, Sandholdt H, Siersma V, Andersen CL, et al. The development of multimorbidity during 16 years after diagnosis of type 2 diabetes. J Comorb. 2018;8(1):2235042X18801658. https://doi.org/10.1177/2235042X18801658.CrossRefPubMedPubMedCentral

30.

Lin P-J, Pope E, Zhou FL. Comorbidity type and health care costs in type 2 diabetes: a retrospective database analysis. Diabetes Ther. 2018;9:1907–18. https://doi.org/10.1007/s13300-018-0477-2.CrossRefPubMedPubMedCentral

31.

Duffield SJ, Ellis BM, Goodson N, Walker-Bone K, Conaghan PG, Margham T, et al. The contribution of musculoskeletal disorders in multimorbidity: implications for practice and policy. Best Pract Res Clin Rheumatol. 2017;31(2):129–44. https://doi.org/10.1016/j.berh.2017.09.004.CrossRefPubMed

32.

Pozzobon D, Ferreira PH, Dario AB, Almeida L, Vesentini G, Harmer AR, et al. Is there an association between diabetes and neck and back pain? A systematic review with meta-analyses. PLoS One. 2019;14(2):e0212030. https://doi.org/10.1371/journal.pone.0212030.CrossRefPubMedPubMedCentral

33.

Berenbaum F. Diabetes-induced osteoarthritis: from a new paradigm to a new phenotype. Ann Rheum Dis. 2011;70(8):1354–6. https://doi.org/10.1136/pgmj.2010.146399.CrossRefPubMed

34.

Cannata F, Vadalà G, Ambrosio L, Fallucca S, Napoli N, Papalia R, et al. Intervertebral disc degeneration: a focus on obesity and type 2 diabetes. Diabetes Metab Res Rev. 2020;36(1):e3224. https://doi.org/10.1002/dmrr.3224.CrossRefPubMed

35.

Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9:88. https://doi.org/10.1186/1471-2458-9-88.CrossRefPubMedPubMedCentral

36.

Khaledi M, Haghighatdoost F, Feizi A, Aminorroaya A. The prevalence of comorbid depression in patients with type 2 diabetes: an updated systematic review and meta-analysis on huge number of observational studies. Acta Diabetol. 2019;56(6):631–50. https://doi.org/10.1007/s00592-019-01295-9.CrossRefPubMed

37.

Cols-Sagarra C, López-Simarro F, Alonso-Fernández M, Mancera-Romero J, Pérez-Unanua MP, Mediavilla-Bravo JJ, et al. Work Group of Diabetes SEMERGEN (Sociedad Española de Médicos de Atención Primaria). Prevalence of depression in patients with type 2 diabetes attended in primary care in Spain. Prim Care Diabetes. 2016;10(5):369–75. https://doi.org/10.1016/j.pcd.2016.02.003.CrossRefPubMed

38.

Alajmani DSA, Alkaabi AM, Alhosani MW, Folad AA, Abdouli FA, Carrick FR, et al. Prevalence of undiagnosed depression in patients with type 2 diabetes. Front Endocrinol (Lausanne). 2019;10:259. https://doi.org/10.3389/fendo.2019.00259.CrossRef

39.

Udedi M, Pence BW, Stewart RC, Muula AS. Detection and prevalence of depression among adult type 2 diabetes mellitus patients attending non-communicable diseases clinics in Lilongwe, Malawi. Int J Ment Health Syst. 2020;14(1):79. https://doi.org/10.1186/s13033-020-00413-3.CrossRefPubMedPubMedCentral

40.

Farooqi A, Khunti K, Abner S, Gillies C, Morriss R, Seidu S. Comorbid depression and risk of cardiac events and cardiac mortality in people with diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2019;156:107816. https://doi.org/10.1016/j.diabres.2019.107816.CrossRefPubMed

41.

van der Feltz-Cornelis C, Allen SF, Holt RIG, Roberts R, Nouwen A, Sartorius N. Treatment for comorbid depressive disorder or subthreshold depression in diabetes mellitus: systematic review and meta-analysis. Brain Behav. 2021;11(2):e01981. https://doi.org/10.1002/brb3.1981.CrossRefPubMed

42.

Lin P-J, Kent DM, Winn AN, Cohen JT, Neumann PJ. Multiple chronic conditions in type 2 diabetes mellitus: prevalence and consequences. Am J Manag Care. 2015;21(1):e23-34.PubMed

Title: Multimorbidity and achievement of treatment goals among patients with type 2 diabetes: a primary care, real-world study
Authors: Eveliina Heikkala
Ilona Mikkola
Jari Jokelainen
Markku Timonen
Maria Hagnäs
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Care
Type 2 Diabetes
Published in: BMC Health Services Research / Issue 1/2021
Electronic ISSN: 1472-6963
DOI: https://doi.org/10.1186/s12913-021-06989-x

At a glance: The STEP trials

Springer Medicine

Multimorbidity and achievement of treatment goals among patients with type 2 diabetes: a primary care, real-world study

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Lack of recognition at the societal level heightens turnover considerations among Nordic eldercare workers: a quantitative analysis of survey data

The impacts of family physician plan and health transformation plan on hospitalization rates in Iran: an interrupted time series

The combination of psychosocial working conditions, occupational balance and sociodemographic characteristics and their associations with no or negligible stress symptoms among Swedish occupational therapists – a cross-sectional study

Understanding HPV-positive women’s needs and experiences in relation to patient-provider communication issues: a qualitative study

Analysing the expenditure on childbearing: a community-based cross-sectional study in rural areas of Punjab (India)

Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials